Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
This article was originally published in The Tan Sheet
Executive Summary
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
You may also be interested in...
Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong
GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
FDA Guidance Raises Prospect Of More INDs For Supplement Research
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
NAC’s Longevity In US Dietary Supplement Market Swings On Comments As NDI Notifications
FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.